Regeneron Pharmaceuticals Inc (REGN) : Gsa Capital Partners Llp scooped up 12,551 additional shares in Regeneron Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 20,938 shares of Regeneron Pharmaceuticals Inc which is valued at $7.7 Million.Regeneron Pharmaceuticals Inc makes up approximately 0.50% of Gsa Capital Partners Llp’s portfolio.
Other Hedge Funds, Including , Bessemer Group Inc boosted its stake in REGN in the latest quarter, The investment management firm added 171 additional shares and now holds a total of 548 shares of Regeneron Pharmaceuticals Inc which is valued at $202,464.Tiaa Cref Investment Management reduced its stake in REGN by selling 6,468 shares or 2.05% in the most recent quarter. The Hedge Fund company now holds 308,396 shares of REGN which is valued at $114.1 Million. Regeneron Pharmaceuticals Inc makes up approx 0.09% of Tiaa Cref Investment Management’s portfolio. Sandy Spring Bank added REGN to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $36,995. Exane Asset Management added REGN to its portfolio by purchasing 40 company shares during the most recent quarter which is valued at $14,798. Regeneron Pharmaceuticals Inc makes up approx 0.01% of Exane Asset Management’s portfolio.
Regeneron Pharmaceuticals Inc opened for trading at $380 and hit $394.4699 on the upside on Monday, eventually ending the session at $391.95, with a gain of 6.09% or 22.49 points. The heightened volatility saw the trading volume jump to 13,04,336 shares. Company has a market cap of $41,186 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.55. The company had revenue of $1201.00 million for the quarter, compared to analysts expectations of $1178.39 million. The company’s revenue was up 38.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.88 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.